Navigation Links
One-year results from Horizons-AMI trial reported at TCT 2009
Date:9/21/2009

d the impact of bivalirudin versus unfractionated heparin (UFH) plus a glycoprotein IIb/IIIa inhibitor (GPI) on clinical outcomes in patients with STEMI undergoing primary PCI of the LAD.

In the international, large-scale prospective HORIZONS-AMI trial (Principal Investigator: Gregg Stone, MD), 3,602 patients were randomized to bivalirudin monotherapy vs. UFH+GPI. Of these, 1,445 patients underwent primary PCI of the LAD, whereas 1,884 patients underwent primary PCI of only non-LAD lesions. The occurrence of MACE (death, reinfarction, ischemic target vessel revascularization or stroke), major bleeding and net adverse clinical events (NACE = MACE or major bleeding) at 12 months were assessed in the two groups.

In comparing patients undergoing LAD versus non-LAD primary PCI, the rates of net adverse clinical events (19.3% vs. 15.4%), MACE (14.1% vs. 10.3%), death (5.6% vs. 2.8%) and cardiac death (4.2% vs. 1.9%) were significantly higher (all p<0.05) in LAD patients, whereas the rates of major bleeding (8.4% vs. 7.3%, p=0.27) and stent thrombosis (3.4% both) did not significantly differ.

Patients with LAD lesions were also randomized to treatment with bivalirudin (N=699) or UFH+GPI (N=746). The baseline clinical and angiographic features were well matched between these groups. "In patients treated with bivalirudin as compared to UFH+GPI, NACE (18.3% vs. 20.2%, p=0.31) and MACE (14.0% vs. 14.2%, p=0.90) did not significantly differ, whereas major bleeding (6.5% vs. 10.1%, p=0.01) and cardiac death (3.0% vs. 5.3%, p=0.04) were significantly lower in bivalirudin treated patients," said Dr. Whrle.

Patients undergoing primary PCI of LAD as compared to non-LAD lesions had significantly higher one-year rates of NACE, MACE, death and cardiac death. In patients undergoing PCI of LAD lesions, anticoagulation with bivalirudin monotherapy rather than unfractionated heparin + GPI resulted in significant lower rates of major bleeding and cardiac
'/>"/>

Contact: Judy Romero
jromero@crf.org
347-407-2774
Cardiovascular Research Foundation
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. 132 Members of Congress Urge One-Year Delay in Controversial Medicare Bidding Program for Home Medical Equipment
2. INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
3. New type of sirolimus-eluting stent demonstrates superior results
4. Details Emerge About Approach, Results of First US Face Transplant
5. Instrumentation Laboratory Announces Passion & Results Award Winners
6. Bioniche Reports Fiscal 2009 Year-End Results
7. Results of Ongoing Testing Show Air Quality is Safe Near Schools in Beaver and Erie Counties in Pennsylvania
8. Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results
9. PRO-DEX, INC. Announces Fiscal 2009 Fourth Quarter and Full-year Results
10. Immucor to Announce Fiscal First Quarter Financial Results on Thursday, October 1, 2009
11. Neogen Corporation Announces 1st Quarter Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... through national AAD program ,, SCHAUMBURG, ... from melanoma, the deadliest form of skin cancer, ... treated, if caught early. That,s why thousands of ... screenings in their communities through the American Academy ... The program recently reached a milestone - two ...
(Date:12/16/2009)... -- For ages, people from around the world have ... soothing waters have a reputation that dates back over ... miracles. Now, with the introduction of two bath salt ... the legendary benefits of Dead Sea salt in their ... all-natural Dead Sea salt and essential oils - but ...
(Date:12/16/2009)... International, Inc. (OTC Bulletin Board: MZEI) ... Board of Medizone New Zealand Ltd., a joint ... 50% interest, agreed on December 14, 2009 to ... International all global marketing rights of the company,s ... Marshall said, "Time has eroded the relevance of ...
(Date:12/16/2009)... While many of the,pharma companies are struggling ... and inmarket drugs, MarketsandMarkets on the other ... players. These pharma,forecasting solutions are designed for ... phase,III. These have a substantial impact on ... strategy, manufacturing planning, sales force,promotion, and planning. ...
(Date:12/16/2009)... could improve care, but privacy a concern, doctors ... U.S. physicians support the use of electronic medical ... two new studies show. , One study of ... in Massachusetts found that 86 percent believed electronic ... of care, 70 percent thought it would reduce ...
Breaking Medicine News(10 mins):Health News:Dermatologists Reach Skin Cancer Screening Milestone 2Health News:Dermatologists Reach Skin Cancer Screening Milestone 3Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:Pros and Cons of Electronic Medical Records Weighed 2
... (NEWARK, N.J., Oct. 3,2007) Rutgers College of Nursing faculty ... of the Nurse Educator of the New York Times 2007 ... three practicing nurses and one nurse educator from hundreds of ... The winners will be featured in a special section in ...
... , WEDNESDAY, Oct. 3 (HealthDay News) -- Identifying a ... best chemotherapy for patients, U.S. research suggests. , "We ... likely to respond to standard first-line therapy and which ... second-line therapy, based on gene expression profiling," lead author ...
... The screen uses CT scans and is performed without ... new study supports the effectiveness of an innovative form ... sent through a patient,s colon. , When it ... so-called "virtual colonoscopy" is just as effective as the ...
... WEDNESDAY, Oct. 3 (HealthDay News) -- Drug-coated stents offered ... patients with blocked coronary arteries, a large Canadian study ... artery become blocked again after stent implant -- was ... getting drug-coated stents, 7.4 percent versus 10.7 percent. The ...
... WHNN radio personality,Bob Hughes, a well-known voice in the Saginaw ... is moving to Saginaw this,month. "My hearing became damaged ... the quality of my life has changed significantly since being,fitted ... Hearing,",says Hughes. "I am really enjoying my new ears." ...
... UNION CITY, Calif., Oct. 3 Abaxis, Inc.,(Nasdaq: ... point-of-care,blood chemistry analysis systems, announced today the launch ... conjunction with the Piccolo xpress(TM) point of,care analyzer. ... specifically for imaging and,radiology centers in the United ...
Other Medicine News:Health News:Rutgers College of Nursing faculty member Rachel Jones wins New York Times Nurse Award 2Health News:Gene Tests Match Up Lung Tumors, Best Treatment 2Health News:'Virtual' Colonoscopy an Effective Option: Study 2Health News:'Virtual' Colonoscopy an Effective Option: Study 3Health News:Study Finds Benefits With Drug-Coated Stents 2Health News:Study Finds Benefits With Drug-Coated Stents 3Health News:WHNN's Bob Hughes Fitted With Hearing Aids by Mobile Care Hearing Clinic Now Serving Saginaw Area 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 3
(Date:12/16/2009)... 16 Optimer Pharmaceuticals, Inc. (Nasdaq: ... 28th Annual J.P. Morgan Healthcare Conference at the ... Wednesday, January 13, 2010. Michael N. Chang, Optimer,s ... 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). ... audio webcast of this presentation will be accessible ...
(Date:12/16/2009)... 16 , ... Microplasmin Recruits a Total of Over,640 patients ... ThromboGenics NV (Euronext Brussels: THR), a ... of innovative treatments for eye,disease, vascular disease ... completed,the enrolment of the second Phase III ...
(Date:12/15/2009)... Inc., a global leader focused on improving blood collection, ... to provide blood centers with Alyx® system supplies needed ... filed yesterday against Fenwal by Haemonetics Corporation ( HAE). ... an advanced medical instrument used worldwide to collect two ... about 30 minutes. ,, Fenwal will ask ...
Breaking Medicine Technology:Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 2Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 3Ethiopias climate 27 million years ago had higher rainfall warmer soil 10491 1Ethiopias climate 27 million years ago had higher rainfall warmer soil 10491 2Syphilis survey reveals need for accurate testing for early infection 59960 1RIT scientist shines laser light on methane in pursuit of clean fuel 10490 1RIT scientist shines laser light on methane in pursuit of clean fuel 10490 2
... Computerized tomographic (CT),colonography, also known as virtual colonoscopy, ... flexible tube with a camera to view the,lining ... detect cancer and,precancerous polyps and could serve as ... the results of the American College of,Radiology Imaging ...
... Biotech has become,aware of preliminary data from an ... in patients with acute ischemic stroke. In,this study, ... with,Epoetin alfa within six hours of the onset ... placebo. Ortho Biotech has reported this,information to the ...
Other Medicine Technology:Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 2Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 3Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: